Related Experiment Videos
[Interstitial granulomatous dermatitis without arthritis: successful therapy with hydroxychloroquine]
Eva Kristina Gerbing1, Dieter Metze, Thomas A Luger
1Universitäts-Hautklinik Münster.
Summary
Interstitial granulomatous dermatitis, a rare skin condition, presents with a distinct "rope sign." This case highlights its varied presentation and successful treatment with hydroxychloroquine.
Area of Science:
- Dermatology
- Rheumatology
Background:
- Interstitial granulomatous dermatitis is a rare condition.
- It is characterized by specific histological features and often associated with rheumatoid arthritis.
Observation:
- A 60-year-old patient presented with erythematous patches and an indurated, violaceous border resembling the "rope sign."
- Histological examination revealed dense interstitial inflammatory infiltrates and eosinophilic degenerated collagen fibres (the "floating sign").
- Unlike most cases, this patient did not report arthralgias.
Findings:
- The histological findings were consistent with interstitial granulomatous dermatitis.
- The patient's skin lesions resolved after treatment with hydroxychloroquine.
Implications:
- This case expands the understanding of interstitial granulomatous dermatitis's clinical spectrum.
- Hydroxychloroquine may be an effective treatment option for this rare dermatosis.
Related Concept Videos
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:12Chronic Inflammation: Introduction
Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...